An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Rabeprazole; Rifampicin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology.
- 22 Apr 2017 Status changed from active, no longer recruiting to completed.
- 23 Sep 2016 Planned End Date changed from 1 Feb 2016 to 1 Nov 2016.